Has Sara Brown received payments from drug or device companies?

Yes. Drug and device makers reported $7,129 in general payments to Sara Brown across 172 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sara Brown did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sara Brown come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sara Brown

Community Health · Riverside, RINPI 1902823909

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,659 and has fallen 93.8% since, to $229 in 2024.

$7,129in general payments, 2019–2025

Across 172 payments — averaging $41.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$1K
Johnson & Johnson$867
Biohaven Pharmaceuticals, Inc.$673
Boehringer Ingelheim$651
Novo Nordisk$648
AstraZeneca$447
plus $3K from 18 others

What the payments were for

Food & beverage$7,129100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	27	$1,156
Johnson & Johnson(2 entities)	20	$867
Biohaven Pharmaceuticals, Inc.	12	$673
Boehringer Ingelheim	9	$651
Novo Nordisk	16	$648
AstraZeneca	11	$447
Sanofi-aventis U.S. LLC	13	$365
AbbVie(2 entities)	15	$340
Lilly USA, LLC	4	$330
Amgen	3	$322
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$258
Biohaven Pharmaceutical Holding Company Ltd.	7	$203
Abbott	2	$163
Bayer	3	$161
Pfizer	9	$149
Mylan Specialty L.p.	2	$109
Novartis	5	$96
Merck	4	$59
Amarin Pharma, Inc.	2	$35
Astellas Pharma US Inc	1	$22
Nestle Healthcare Nutrition Inc.	1	$21
Teva Pharmaceuticals USA, Inc.	1	$19
Xeris Pharmaceuticals, Inc.	1	$17
Paratek Pharmaceuticals, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few community health providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Atorvastatin Calcium	11	$72

Paid to pharmacies, not to this prescriber.

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →